{"id":52135,"date":"2023-09-20T09:29:28","date_gmt":"2023-09-20T09:29:28","guid":{"rendered":"https:\/\/medsname.com\/acamptas-333-mg\/"},"modified":"2026-05-01T10:49:12","modified_gmt":"2026-05-01T10:49:12","slug":"acamptas-333-mg","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/acamptas-333-mg\/","title":{"rendered":"Acamptas 333 Mg"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Rychl\u00e1 odpov\u011b\u010f \u2014 Acamptas 333 Mg \u2014 akampros\u00e1t 333 mg (s prodlou\u017een\u00fdm uvol\u0148ov\u00e1n\u00edm) pro udr\u017een\u00ed abstinence od alkoholu<\/h3>\n

Acamptas 333 Mg je akampros\u00e1t v\u00e1penat\u00fd 333 mg (s prodlou\u017een\u00fdm uvol\u0148ov\u00e1n\u00edm), modul\u00e1tor NMDA\/glutam\u00e1tu, kter\u00fd pom\u00e1h\u00e1 udr\u017eet abstinenci od alkoholu pot\u00e9, co pacient ji\u017e p\u0159estal p\u00edt. Standardn\u00ed d\u00e1vka je dv\u011b tablety 333 mg t\u0159ikr\u00e1t denn\u011b<\/strong> (1 998 mg\/den) s j\u00eddlem. Nel\u00e9\u010d\u00ed akutn\u00ed abstinen\u010dn\u00ed p\u0159\u00edznaky a nevyvol\u00e1v\u00e1 averzn\u00ed reakci; \u00fa\u010dinek se projevuje postupn\u011b b\u011bhem 4\u201312 t\u00fddn\u016f. Nejlep\u0161\u00edch v\u00fdsledk\u016f dosahuje v kombinaci s terapi\u00ed. \u00daprava d\u00e1vkov\u00e1n\u00ed p\u0159i ren\u00e1ln\u00ed insuficienci; kontraindikov\u00e1no p\u0159i t\u011b\u017ek\u00e9m po\u0161kozen\u00ed ledvin.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n

Co je Acamptas 333 Mg?<\/h2>\n

Acamptas 333 Mg je udr\u017eovac\u00ed l\u00e9k na poruchy u\u017e\u00edv\u00e1n\u00ed alkoholu obsahuj\u00edc\u00ed acampros\u00e1t v\u00e1penat\u00fd 333 mg (s prodlou\u017een\u00fdm uvol\u0148ov\u00e1n\u00edm)<\/strong> (tablety s enterick\u00fdm potahem), dod\u00e1van\u00e9 spole\u010dnost\u00ed Intas Pharmaceuticals. Je to jedna ze dvou prvn\u00edch lini\u00ed peror\u00e1ln\u00ed farmakoterapie pro poruchy u\u017e\u00edv\u00e1n\u00ed alkoholu (spolu s naltrexonem) v modern\u00edch sm\u011brnic\u00edch v\u010detn\u011b FDA, EMA, NICE a APA. Strukturn\u011b je podobn\u00fd aminokyselinov\u00e9mu neurotransmiteru taurinu a nem\u00e1 \u00fa\u010dinky zneu\u017eit\u00ed, sedativn\u00ed nebo anxiolytick\u00e9.<\/p>\n

Jak acampros\u00e1t funguje<\/h2>\n

Chronick\u00e9 nadm\u011brn\u00e9 pit\u00ed alkoholu vyvol\u00e1v\u00e1 dlouhodobou up-regulaci NMDA glutam\u00e1tov\u00fdch receptor\u016f<\/strong> a down-regulaci GABA-A receptor\u016f<\/strong> jak se mozek p\u0159izp\u016fsobuje GABAergn\u00edmu a anti-glutam\u00e1tergn\u00edmu \u00fa\u010dinku alkoholu. Kdy\u017e pacient p\u0159estane p\u00edt, vznik\u00e1 relativn\u00ed glutam\u00e1tov\u00e1 hyperaktivita<\/strong> stav, kter\u00fd zp\u016fsobuje n\u011bkolik m\u011bs\u00edc\u016f p\u0159\u00edznak\u016f po ukon\u010den\u00ed konzumace \u2014 nespavost, \u00fazkost, podr\u00e1\u017ed\u011bnost, fragmentaci sp\u00e1nku, anhedonii, dysforii \u2014 souhrnn\u011b protrahovan\u00fd abstinen\u010dn\u00ed syndrom. Tyto p\u0159\u00edznaky jsou nejsiln\u011bj\u0161\u00edm farmakologick\u00fdm faktorem pozdn\u00edho relapsu.<\/p>\n

Acampros\u00e1t pravd\u011bpodobn\u011b moduluje funkci NMDA-receptor\u016f<\/strong> (pravd\u011bpodobn\u011b jako parci\u00e1ln\u00ed agonista na glycin-vazebn\u00e9m m\u00edst\u011b, s vedlej\u0161\u00edmi \u00fa\u010dinky na typ-1 metabotropn\u00ed glutam\u00e1tov\u00e9 receptory a nap\u011b\u0165ov\u011b z\u00e1visl\u00e9 kalciov\u00e9 kan\u00e1ly), sni\u017euje glutam\u00e1tovou hyperaktivitu po ukon\u010den\u00ed konzumace a pom\u00e1h\u00e1 mozku znovu dos\u00e1hnout rovnov\u00e1hy. Kl\u00ed\u010dov\u00e9 je, \u017ee, neovliv\u0148uje akutn\u00ed intoxikaci alkoholem ani abstinen\u010dn\u00ed p\u0159\u00edznaky \u2014 je \u010dist\u011b udr\u017eovac\u00edm l\u00e9kem<\/strong>, zah\u00e1j\u00ed se po zvl\u00e1dnut\u00ed abstinen\u010dn\u00edch p\u0159\u00edznak\u016f (obvykle benzodiazepiny).<\/p>\n

Jak se Acamptas 333 Mg pou\u017e\u00edv\u00e1<\/h2>\n\n\n\n\n\n\n
Hmotnost pacienta<\/th>\nD\u00e1vka<\/th>\nPozn\u00e1mky<\/th>\n<\/tr>\n<\/thead>\n
\u2265 60 kg<\/td>\n2 tablety (666 mg) t\u0159ikr\u00e1t denn\u011b<\/strong> (celkem 1 998 mg\/den)<\/td>\nU\u017e\u00edvejte p\u0159i sn\u00eddani, ob\u011bd\u011b a ve\u010de\u0159i<\/td>\n<\/tr>\n
< 60 kg<\/td>\n4 tablety\/den (1 332 mg) rozd\u011blen\u00e9<\/td>\nObvykle 2 tablety r\u00e1no, 1 p\u0159es den, 1 ve\u010der<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

U\u017e\u00edvejte s j\u00eddlem \u2013 akampros\u00e1t m\u00e1 n\u00edzkou biologickou dostupnost (~11 %) a j\u00eddlo v\u00fdrazn\u011b sni\u017euje variabilitu mezi pacienty. Polykejte tablety cel\u00e9<\/strong>; enterosolventn\u00ed povlak chr\u00e1n\u00ed p\u0159ed rozkladem v \u017ealudku, proto tablety nedr\u0165te ani ned\u011blte.<\/p>\n

Akampros\u00e1t se zahajuje po<\/strong> Pacient p\u0159estal p\u00edt a pro\u0161el p\u0159\u00edpadn\u00fdm nutn\u00fdm kontrolovan\u00fdm odvyk\u00e1n\u00edm (obvykle 5\u201310 dn\u00ed po posledn\u00edm n\u00e1poji). Nem\u00e1 vliv na akutn\u00ed abstinen\u010dn\u00ed p\u0159\u00edznaky, tak\u017ee p\u0159\u00edli\u0161 brzk\u00e9 zah\u00e1jen\u00ed nem\u00e1 \u017e\u00e1dn\u00fd benefit. L\u00e9\u010dba obvykle pokra\u010duje po dobu 12 m\u011bs\u00edc\u016f<\/strong>, \u010dasto d\u00e9le u pacient\u016f s vysok\u00fdm rizikem relapsu.<\/p>\n

\u00daprava d\u00e1vkov\u00e1n\u00ed p\u0159i ren\u00e1ln\u00edm posti\u017een\u00ed (povinn\u00e1)<\/h2>\n

Akampros\u00e1t se vylu\u010duje ledvinami v nezm\u011bn\u011bn\u00e9 form\u011b; d\u00e1vku ur\u010duje ren\u00e1ln\u00ed funkce:<\/p>\n\n\n\n\n\n\n\n
eGFR (mL\/min\/1,73 m\u00b2)<\/th>\nD\u00e1vka<\/th>\n<\/tr>\n<\/thead>\n
> 50<\/td>\nStandardn\u00ed d\u00e1vka 666 mg t\u0159ikr\u00e1t denn\u011b<\/td>\n<\/tr>\n
30\u201350<\/td>\n333 mg t\u0159ikr\u00e1t denn\u011b<\/strong> (jedna tableta t\u0159ikr\u00e1t denn\u011b)<\/td>\n<\/tr>\n
< 30<\/td>\nKontraindikov\u00e1no<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n